



14 June 2017

**Motif Bio plc**  
("Motif Bio" or the "Company")

**Presentation at BIO International Convention**

Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the Company will present at BIO 2017 being held at the San Diego Convention Center, 111 West Harbor Drive, San Diego from 19-22 June 2017.

The presentation will provide information on the progress of its novel antibiotic candidate, iclaprim, and will take place at 3.30pm on Wednesday, 21 June in Presentation Theater 3. The presentation will be available shortly after on the company website: [www.motifbio.com](http://www.motifbio.com)

The BIO International Convention brings together over 16,000 biotechnology and pharma leaders, covering a wide spectrum of life sciences areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy – for more information see: <http://convention.bio.org>

**For further details please contact:**

**Motif Bio plc**

Graham Lumsden (Chief Executive Officer)  
Rob Dickey (Chief Financial Officer)

[info@motifbio.com](mailto:info@motifbio.com)

**Peel Hunt LLP (NOMAD & BROKER)**

Dr. Christopher Golden  
Oliver Jackson

+ 44 (0)20 7418 8900

**Northland Capital Partners Limited (BROKER)**

Patrick Claridge/ David Hignell  
John Howes/ Rob Rees (Broking)

+44 (0)20 3861 6625

**Walbrook PR Ltd. (FINANCIAL PR & IR)**

Paul McManus  
Mike Wort

+44 (0)20 7933 8780 or [motifbio@walbrookpr.com](mailto:motifbio@walbrookpr.com)

Mob: +44 (0)7980 541 893

Mob: +44 (0)7900 608 002

**MC Services AG (EUROPEAN IR)**

Raimund Gabriel

+49 (0)89 210 2280

**About Motif Bio:** [www.motifbio.com](http://www.motifbio.com)

Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), infections often caused by MRSA (methicillin resistant *Staphylococcus aureus*). Having completed the REVIVE-1 trial, patients are currently being enrolled and dosed in a second global Phase 3 clinical trial (REVIVE-2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2 is expected in the second half of 2017.